Back

Cardiac myosin inhibitors in hypertrophic cardiomyopathy: the need for precision medicine

European Heart Journal

19 August 2025
Organised by: Logo
Read full article
ESC Journals VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE Myocardial Disease

Contributors

Ali Yilmaz
Ali Yilmaz

Author

University Hospital Munster - UKM Muenster , Germany

You may be interested in
thumbnail
Congress Session
Implications of obstructive hypertrophic cardiomyopathy (oHCM) for heart failure specialists
17 May 2025
thumbnail
Congress Presentation
Narrowing Beta-myosin hot spots in its association with hypertrophic cardiomyopathy
26 August 2022
thumbnail
Congress Presentation
Cardiac myosin inhibitor, mavacamten, improves myocardial relaxation in mouse HFpEF model
30 April 2022
thumbnail
Congress Session
Translating evidence into practice: myosin inhibition across the hypertrophic cardiomyopathy spectrum
30 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources